PITTSBURGH--(BUSINESS WIRE)--Foundation Consumer Healthcare (FCH), a company dedicated to improving consumers’ lives by developing and growing a portfolio of differentiated over-the-counter (OTC) products, has completed the acquisition of Plan B One-Step® and several Value Brands of emergency contraception from Teva Pharmaceutical Industries Ltd. in a $675 million transaction. Plan B One-Step® is the #1 selling OTC SKU in the U.S. and helps prevent unintended pregnancy when used as directed within 72 hours of unprotected sex or birth control failure.
In support of the Plan B One-Step® acquisition, Greg Bradley has joined FCH as President and CEO. With nearly 34 years of experience in the consumer-packaged goods industry, Bradley has a proven track record of improving in-market performance of existing OTC healthcare brands. Prior to joining FCH, Bradley spent much of his career with GlaxoSmithKline where he led multiple prescription to OTC product switches and in 2011, Bradley founded Advantage Consumer Healthcare (ACH), a full-service company specializing in OTC switches and healthcare product launches. FCH will continue to work with ACH as their OTC selling team.
“As the #1 OB/GYN recommended OTC emergency contraceptive brand and an important birth control option for women across the U.S., Plan B One-Step® is the perfect addition to our growing portfolio,” stated Bradley. “We look forward to devoting immense resources to support Plan B One-Step® and working closely with our retail partners to ensure continued access to this critical women’s health product.”
Formed in 2014, FCH markets a diverse portfolio of differentiated OTC products including Neo-Synephrine®, Campho-Phenique®, Bronkaid®, St. Joseph® Aspirin and Theravent®. With increased investment and category growth, a commitment to innovation and an eye toward additional acquisitions, the future is bright for FCH and its retail partners.
In addition to Bradley, FCH is led by industry veterans with nearly 80 years of collective experience in the development, marketing and commercialization of prescription and OTC medicines at notable OTC companies, including:
- May Petracco, Chief Financial Officer
- Steve Howard, Chief Marketing Officer
- Tara Evans, Marketing Director of Women’s Health
- Doug Lusby, Senior Vice President of Supply Chain Operations
“The senior leadership team at FCH is dedicated to supporting innovative therapies and focused on driving growth across our product portfolio,” said Bradley. “As the category leader, Plan B One-Step® plays an important role in women’s health, and FCH is eager to invest the resources and thinking necessary to help Plan B One-Step® fulfill that role.”
About Foundation Consumer Healthcare
Formed in 2014, Foundation Consumer Healthcare (FCH) is dedicated to improving consumers’ lives by developing and growing a portfolio of differentiated over-the-counter (OTC) products including Plan B One Step®, Theravent® Snore Therapy Strips, Campho-Phenique® Healing Gel & Liquid, St. Joseph® 81 mg Aspirin, Bronkaid® Dual Action Asthma Caplets and Neo-Synephrine® Nasal Spray. FCH’s management team is comprised of industry leaders with unparalleled experience in the development, marketing and commercialization of prescription and non-prescription medicines. FCH is backed by Juggernaut Capital Partner and Kelso & Company, two private equity firms with successful histories in the OTC marketplace and commitment to building a diverse portfolio of brands under the FCH banner. FCH is based in Pittsburgh, PA, with additional team members located throughout the country. For additional information, visit https://foundationch.com.
About Plan B One-Step®
Plan B One-Step® (levonorgestrel) 1.5 mg tablet is a progestin-only emergency contraceptive that helps prevent pregnancy when taken within 72 hours (3 days) after birth control failure or unprotected sex. The sooner it’s taken, the better it works. Plan B One-Step® works mainly by stopping the release of an egg from the ovary. It is possible that Plan B One-Step® may also work by preventing fertilization of an egg (the uniting of sperm with the egg) or by preventing attachment (implantation) to the uterus (womb). When used as directed, about 7 out of every 8 women who would have gotten pregnant will not become pregnant after taking Plan B One-Step®. Plan B One-Step® is not an abortion pill; it will not work if a woman is already pregnant and will not affect an existing pregnancy. Plan B One-Step® is a back-up method of preventing pregnancy, and should not be used as regular birth control because it is not as effective. Side effects may include menstrual changes, nausea, lower stomach (abdominal) pain, tiredness, headache, dizziness, breast pain and vomiting. Plan B One-Step® does not protect a woman against HIV/AIDS or sexually transmitted diseases (STDs). For additional information, visit www.PlanBOneStep.com.